Results

RDF/XMLNTriplesTurtleShow queryShare ▶
SubjectPredicateObject
http://purl.uniprot.org/citations/24597466http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/24597466http://www.w3.org/2000/01/rdf-schema#comment"

Objective

To systematically review evidence on genetic risk factors for carbamazepine (CBZ)-induced hypersensitivity reactions (HSRs) and provide practice recommendations addressing the key questions: (1) Should genetic testing for HLA-B*15:02 and HLA-A*31:01 be performed in patients with an indication for CBZ therapy to reduce the occurrence of CBZ-induced HSRs? (2) Are there subgroups of patients who may benefit more from genetic testing for HLA-B*15:02 or HLA-A*31:01 compared to others? (3) How should patients with an indication for CBZ therapy be managed based on their genetic test results?

Methods

A systematic literature search was performed for HLA-B*15:02 and HLA-A*31:01 and their association with CBZ-induced HSRs. Evidence was critically appraised and clinical practice recommendations were developed based on expert group consensus.

Results

Patients carrying HLA-B*15:02 are at strongly increased risk for CBZ-induced Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) in populations where HLA-B*15:02 is common, but not CBZ-induced hypersensitivity syndrome (HSS) or maculopapular exanthema (MPE). HLA-B*15:02-positive patients with CBZ-SJS/TEN have been reported from Asian countries only, including China, Thailand, Malaysia, and India. HLA-B*15:02 is rare among Caucasians or Japanese; no HLA-B*15:02-positive patients with CBZ-SJS/TEN have been reported so far in these groups. HLA-A*31:01-positive patients are at increased risk for CBZ-induced HSS and MPE, and possibly SJS/TEN and acute generalized exanthematous pustulosis (AGEP). This association has been shown in Caucasian, Japanese, Korean, Chinese, and patients of mixed origin; however, HLA-A*31:01 is common in most ethnic groups. Not all patients carrying either risk variant develop an HSR, resulting in a relatively low positive predictive value of the genetic tests.

Significance

This review provides the latest update on genetic markers for CBZ HSRs, clinical practice recommendations as a basis for informed decision making regarding the use of HLA-B*15:02 and HLA-A*31:01 genetic testing in patients with an indication for CBZ therapy, and identifies knowledge gaps to guide future research. A PowerPoint slide summarizing this article is available for download in the Supporting Information section here."xsd:string
http://purl.uniprot.org/citations/24597466http://purl.org/dc/terms/identifier"doi:10.1111/epi.12564"xsd:string
http://purl.uniprot.org/citations/24597466http://purl.uniprot.org/core/author"Connolly M.B."xsd:string
http://purl.uniprot.org/citations/24597466http://purl.uniprot.org/core/author"Ito S."xsd:string
http://purl.uniprot.org/citations/24597466http://purl.uniprot.org/core/author"Nakamura H."xsd:string
http://purl.uniprot.org/citations/24597466http://purl.uniprot.org/core/author"Rieder M.J."xsd:string
http://purl.uniprot.org/citations/24597466http://purl.uniprot.org/core/author"Hwang S."xsd:string
http://purl.uniprot.org/citations/24597466http://purl.uniprot.org/core/author"Fung V."xsd:string
http://purl.uniprot.org/citations/24597466http://purl.uniprot.org/core/author"Shear N.H."xsd:string
http://purl.uniprot.org/citations/24597466http://purl.uniprot.org/core/author"Carleton B.C."xsd:string
http://purl.uniprot.org/citations/24597466http://purl.uniprot.org/core/author"Amstutz U."xsd:string
http://purl.uniprot.org/citations/24597466http://purl.uniprot.org/core/date"2014"xsd:gYear
http://purl.uniprot.org/citations/24597466http://purl.uniprot.org/core/name"Epilepsia"xsd:string
http://purl.uniprot.org/citations/24597466http://purl.uniprot.org/core/pages"496-506"xsd:string
http://purl.uniprot.org/citations/24597466http://purl.uniprot.org/core/title"Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions."xsd:string
http://purl.uniprot.org/citations/24597466http://purl.uniprot.org/core/volume"55"xsd:string
http://purl.uniprot.org/citations/24597466http://www.w3.org/2004/02/skos/core#exactMatchhttp://purl.uniprot.org/pubmed/24597466
http://purl.uniprot.org/citations/24597466http://xmlns.com/foaf/0.1/primaryTopicOfhttps://pubmed.ncbi.nlm.nih.gov/24597466
http://purl.uniprot.org/uniprot/#_A0A0A7C543-mappedCitation-24597466http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/24597466
http://purl.uniprot.org/uniprot/#_A0A0A7C548-mappedCitation-24597466http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/24597466
http://purl.uniprot.org/uniprot/#_A0A0A7C551-mappedCitation-24597466http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/24597466
http://purl.uniprot.org/uniprot/#_A0A0A7C552-mappedCitation-24597466http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/24597466
http://purl.uniprot.org/uniprot/#_A0A0E3DC98-mappedCitation-24597466http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/24597466
http://purl.uniprot.org/uniprot/#_A0A0E3DCA0-mappedCitation-24597466http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/24597466
▶